Ishida H, Bellows C G, Aubin J E, Heersche J N
M.R.C. Group in Periodontal Physiology, Faculty of Dentistry, University of Toronto, Ontario, Canada.
Endocrinology. 1993 Jan;132(1):61-6. doi: 10.1210/endo.132.1.8419147.
We investigated the effects of 1,25-dihydroxyvitamin D3[1,25-(OH)2D3], on osteoprogenitor cell differentiation and bone nodule formation at various stages of differentiation by evaluating the effects on long term cultures of fetal rat calvaria (RC) cells. RC cells were plated at 3 x 10(4) cells/35-mm dish in alpha-minimal essential medium containing 15% fetal bovine serum, ascorbic acid, and beta-glycerophosphate (beta-GP), conditions under which bone nodules form. 1,25-(OH)2D3 inhibited bone nodule formation in a dose-dependent manner with total inhibition occurring at 1-10 nM and half-maximal inhibition occurring at approximately 0.06 nM. 1,25-(OH)2D3 also significantly stimulated RC cell growth in a dose-dependent manner in both the presence and absence of ascorbic acid. Addition of 1 nM 1,25-(OH)2D3 at different times after the start of culture inhibited nodule formation when added before and up to the early multilayering stage (up to day 11 of culture), but had no effect on nodule number when added later. When 1,25-(OH)2D3 was added at the start of the culture period and removed at the early multilayering stage, nodule formation was also inhibited. Pulses of 48-h duration also inhibited nodule formation, with maximal effect occurring between days 3 and 11. Thus, 1,25-(OH)2D3 inhibited osteoprogenitor cell differentiation during the earlier stages of culture before visible bone nodule formation occurred and the effect was not reversible upon removal of 1,25-(OH)2D3. In cultures grown to the multilayering stage in medium without ascorbic acid and beta-GP and then changed to medium with ascorbic acid and beta-GP, 1,25-(OH)2D3 inhibited when present before, but not after, the addition of ascorbic acid and beta-GP. Two other vitamin D3 metabolites, 24,25-dihydroxyvitamin D3 [24,25-(OH)2D3] and 1,24,25-trihydroxyvitamin D3 [1,24,25-(OH)3D3] had inhibitory effects similar to 1,25-(OH)2D3. The effects were dose dependent for each metabolite tested and correlated with the biological effectiveness of these metabolites in other systems: i.e. 1,25-(OH)2D3 was more effective than 1,24,25-(OH)3D3 which in turn was more effective than 24,25-(OH)2D3. The data show that 1,25-(OH)2D3 inhibits osteoprogenitor cell differentiation at an early stage and at a time during which cell growth is stimulated.
我们通过评估1,25 - 二羟基维生素D3[1,25-(OH)2D3]对胎鼠颅骨(RC)细胞长期培养的影响,研究了其在不同分化阶段对成骨祖细胞分化和骨结节形成的作用。将RC细胞以3×10⁴个细胞/35毫米培养皿接种于含15%胎牛血清、抗坏血酸和β - 甘油磷酸酯(β - GP)的α - 最低必需培养基中,在此条件下会形成骨结节。1,25-(OH)2D3以剂量依赖性方式抑制骨结节形成,在1 - 10 nM时完全抑制,约0.06 nM时出现半数最大抑制。在有和没有抗坏血酸的情况下,1,25-(OH)2D3也均以剂量依赖性方式显著刺激RC细胞生长。培养开始后不同时间添加1 nM 1,25-(OH)2D3,在培养至早期多层阶段(培养第11天之前)添加均抑制结节形成,但在后期添加则对结节数量无影响。当在培养期开始时添加1,25-(OH)2D3并在早期多层阶段去除时,结节形成也受到抑制。持续48小时的脉冲也抑制结节形成,最大作用出现在第3天至第11天之间。因此,在可见骨结节形成之前的培养早期阶段,1,25-(OH)2D3抑制成骨祖细胞分化,且去除1,25-(OH)2D3后该作用不可逆。在不含抗坏血酸和β - GP的培养基中培养至多层阶段,然后更换为含抗坏血酸和β - GP的培养基时,1,25-(OH)2D3在添加抗坏血酸和β - GP之前存在时抑制,之后则无抑制作用。另外两种维生素D3代谢产物,24,25 - 二羟基维生素D3[24,25-(OH)2D3]和1,24,25 - 三羟基维生素D3[1,24,25-(OH)3D3]具有与1,25-(OH)2D3相似的抑制作用。对于所测试的每种代谢产物,其作用均呈剂量依赖性,并且与这些代谢产物在其他系统中的生物学活性相关:即1,25-(OH)2D3比1,24,25-(OH)3D3更有效,而1,24,25-(OH)3D3又比24,25-(OH)2D3更有效。数据表明,1,25-(OH)2D3在早期阶段且在刺激细胞生长的同时抑制成骨祖细胞分化。